Cyclooxygenase-2 Immunoexpression in Invasive Breast Carcinoma: A Possible Prognostic Factor

Maryam Abdulmajed  Muhammad Ameen; Jalal Ali  Jalal; Wahda Muhammed Taib Alnuaimy

doi:10.56056/amj.2018.39

Authors

Maryam Abdulmajed Muhammad Ameen Department of Histopathology, Rizgary Teaching Hospital, Erbil
Jalal Ali Jalal Department of Pathology, College of Medicine, HMU, Erbil
Wahda Muhammed Taib Alnuaimy Department of Pathology, College of Medicine, University of Mosul

DOI:

https://doi.org/10.56056/amj.2018.39

Keywords:

Cylooxygenase-2, Immunohistochemistry, Invasive breast carcinoma

Abstract

Background and objectives:cyclooxygenase-2 is well known to be overexpressed in breast cancer and it plays nega- tive effects on tumor growth and progression. The aims of this study were to determine the frequency of Cyclooxygen- ase-2 immunoexpression in invasive breast carcinoma and to evaluate its relationship with some clinicopathological parameters.

Methods: During the period January 2015 to July 2016, 100 formalin-fixed, paraffin-embedded tissue specimens of invasive breast carcinoma were collected from pathology departments of Rizgary teaching hospital and private labs in Erbil city. Using labeled polymer and enhanced polymer system (DakoEnVisionTMFlex) Dakoprotocol, Cyclooxygenase-2 expression was assessed immunohistochemically.

Results:The Cyclooxygenase-2 immunoexpres- sion was detected in 48% of invasive breast carcinoma. A statistically significant association was found between Cyclooxygenase-2 immunoexpression and lymphovascular invasion. Also a rising trend of Cyclooxygenase-2 immu- noexpression was observed with increasing age, tumor size and tumor stage but didn’t reach a statistically significant level. No any statistical significant association was found between Cyclooxygenase-2 immunoexpression and tumor grade.

Conclusions:cyclooxygenase-2 overexpression is observed in 48% of cases of invasive breast carcinoma and was significantly correlated to lymphovascular invasion.

Downloads

Download data is not yet available.

References

Pakkiri P, Lakhani SR, Smart CE. Current and future approach to the pathologist’s assessment for targeted therapy in breast cancer. Pathol- ogy. 2009; 41: 89-99.

Iraqi Cancer Registry 2012. Iraqi Cancer Board. Ministry of Health, Republic of Iraq, 2015.

Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Horto- bagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti–HER-2 therapy and personalized medicine. Oncologist. 2009; 14: 320-68.

Rozic JG, Chakraborty C, Lala PK. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. IJC. 2001; 93: 497-506.

Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002; 62: 632-5.

Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci. 2003; 24: 96-102.

Ali-Fehmi R, Morris RT, Bandyopadhyay S, Che M, Schimp V, Malone JM, et al. Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma:correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival. AJOG. 2005; 192: 819-25.

Ranger GS, Thomas V, Jewell A, Mokbel K. Elevated cyclooxygen- ase-2 expression correlates with distant metastases in breast cancer. Anticancer rese. 2004; 24:2349-52.

Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M. The role of cyclooxygenase-2 in cell proliferation and cell death in human malig- nancies. Int J Cell Biol. 2010; 2010:17

Chandrasekharan NV, Simmons DL. The cyclooxygenases. Genome biology. 2004; 5: 241.

Ramsay RG, Ciznadija D, Vanevski M, Mantamadiotis T. Transcrip- tional regulation of cyclo-oxygenase expression: three pillars of control. Int J Immunopathol Pharmacol. 2003; 16: 59-67.

Kis B, Snipes JA, Isse T, Nagy K, Busija DW. Putative cyclooxygen- ase-3 expression in rat brain cells. J Cereb Blood Flow Metab. 2003; 23: 1287-92.

Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, et al . Cyclooxygenase in biology and disease. FASEB J. 1998; 12: 1063-73.

Falandry C, Canney PA, Freyer G, Dirix LY. Role of combination ther- apy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Ann Oncol. 2009:mdn693.

Rakha EA. , El-Sayed ME., Lee AH, Elston CW, Grainge MJ, Hodi Z,et al. Prognostic significance of Nottingham histological grade in inva- sive breast carcinoma. J Clin Oncol 2008; 26:3153-8.

Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al.Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 2003; 83: 803-19.

Spizzo G, Gastl G, Wolf D, Gunsilius E, Steurer M, Fong D, et al. Cor- relation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival.. B J Cancer 2003; 88, 574 – 578

Serra KP, Peres RM, Sarian LO, Vassallo J, Pinto GA, de Paiva Sil- va GR, et al. Cyclooxygenase-2 (COX2) and p53 protein expression are interdependent in breast cancer but not associated with clinico-patho- logical surrogate subtypes, tumor aggressiveness and patient survival. Acta histochem. 2016; 118: 176 -82.

Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002; 62: 632 -5.

Denkert C, Winzer KJ, Müller BM, Weichert W, Pest S, Köbel M, et al. Elevated expression of cyclooxygenase 2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer. 2003; 97: 2978-87.

Wülfing P, Diallo R, Müller C, Wülfing C, Poremba C, Heinecke A, et al. Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol . 2003; 129: 375-82.

Witton CJ, Hawe SJ, Cooke TG, Bartlett JM. Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER negative, but not ER positive, breast cancer. Histopathology. 2004; 45: 47-54.

Sivula A, Talvensaari-Mattila A, Lundin J, Joensuu H, Haglund C, Ristimäki A, et al. Association of cyclooxygenase-2 and matrix metal- loproteinase-2 expression in human breast cancer Breast Cancer Res Treat. 2005; 89: 215-20.

Surowiak P, Materna V, Matkowski R, Szczuraszek K, Kornafel J, Wojnar A, et al. Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prog- nostic significance. Breast Cancer Res. 2005; 7: R862- R870.

Gunnarsson C, Jansson A, Holmlund B, Ferraud L, Nordenskjold B, Rutqvist LE, et al. Expression of COX-2 and steroid converting enzymes in breast cancer. Oncol Rep. 2006; 16: 219-24.

Schmitz KJ, Callies R, Wohlschläger J, Kimmig R, Otterbach F, Bohr J, et al. Overexpression of cyclo-oxygenase-2 is an independent predic- tor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways. J Clin Pathol. 2006; 59: 685-91.

Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, Iyama K, et al. Hypoxia-inducible factor 1 is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat. 2008; 110: 465-75.

Zhao X, Goswami M, Pokhriyal N, Ma H, Du H, Yao J, et al. Cy- clooxygenase-2 expression during immortalization and breast cancer progression. Cancer Res. 2008; 68: 467-75

Darb-Esfahani S, Loibl S, Müller BM, Roller M, Denkert C, Komor M, et al. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/ taxane-based chemotherapy. Breast cancer Res. 2009; 11: R69.

Muhammad EM, Edin HS, Guirguis MN, Osman SM. Immunohis- tochemical Cyclooxygenase-2 (COX-2) and P53 Expression in Breast Carcinoma with Correlation to Clinico-Pathological Parameters. Med. J. Cairo Uni. 2013; 81(2).

Kargi A, Uysal M, Bozcuk H, Coskun HS, Savas B, Ozdogan M. The importance of COX-2 expression as prognostic factor in early breast cancer. J BUON. 2013; 18: 579-84.

Lee JA, Bae JW, Woo SU, Kim H, Kim CH. Correlation between COX-2 expression and hormone receptors in invasive ductal breast cancer. J Korean Surg Soc. 2010; 78: 140-8.

Glover JA, Hughes CM, Cantwell MM, Murray LJ. A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive car- cinoma of the breast and invasive breast cancer. Br J Cancer. 2011; 105: 13-7.

Davies G, Salter J, Hills M, Martin LA, Sacks N, Dowsett M. Correla- tion between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res. 2003; 9: 2651-6.

Takeshita E, Osanai T, Higuchi T, Soumaoro LT, Sugihara K. Elevated cyclooxygenase-2 expression is associated with histological grade in invasive ductal breast carcinoma. J Med Dent Sci. 2005; 52: 189-93.

Misron NA, Looi LM, Nik Mustapha NR. Cyclooxygenase-2 expres- sion in invasive breast carcinomas of no special type and correlation with pathological profiles suggest a role in tumorigenesis rather than cancer progression. Asian Pac J Cancer Prev. 2015; 16: 1553-8.

Zhang XH, Huang DP, Guo GL, Chen GR, Zhang HX, Wan L, et al.Coexpression of VEGF-C and COX-2 and its association with lymphang- iogenesis in human breast cancer. BMC cancer. 2008; 8: 4.

Nam E, Lee SN, Im SA, Kim DY, Lee KE, Sung SH. Expression of cyclooxygenase-2 in human breast cancer: relationship with HER-2/ neu and other clinicopathological prognostic factors. Cancer Res Treat. 2005; 37: 165-70.

Cho MH, Yoon JH, Jaegal YJ, Choi YD, Lee JS, Lee JH, et al. Expres- sion of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma. Breast. 2006; 15: 390-8.

Leo C., Faber S., Hentschel B., Hfckel M. and Horn L.C.: The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue. Ann Diagn Pathol. 2006; 10: 327-32.

Dillon M., Stafford A., kelly G., Redmond A., Mcilroy M., Crotty T.,et al.: Cyclooxygenase-2 predicts adverse effects of tamoxifen: A possible mechanism of role for nuclear HER2 in breast cancer patients. Endocr Relat Cancer. 2008; 15:745-53.

Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I, Schmitt FC. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol. 2002; 55: 429-34.

Aggarwal A, Al-Rohil RN, Batra A, Feustel PJ, Jones DM, DiPersio CM. Expression of integrin ?3?1 and cyclooxygenase-2 (COX2) are pos- itively correlated in human breast cancer. BMC cancer. 2014; 14: 459.